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Abstract
Background: Our purpose was to analyze the long-term clinical outcome and to identify prognostic factors after
Linac-based stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) on patients with brain
metastases (BM) from non-small cell lung cancer (NSCLC).
Materials and Methods: We performed a retrospective analysis of survival on 90 patients who underwent SRS or
FSRT of intracranial NSCLC metastases between 04/2004 and 05/2014 that had not undergone prior surgery or
whole brain radiotherapy (WBRT) for BM. Follow-up data was analyzed until May 2015. Potential prognostic factors
were examined in univariable and multivariable analyses. The Golden Grading System (GGS), the disease-specific
graded prognostic assessment (DS-GPA), the RADES II prognostic index as well as the NSCLC-specific index
proposed by Rades et al. in 2013 (NSCLC-RADES) were calculated and their predictive values were tested in
univariable analysis.
Results: The median follow-up time of the surviving patients was 14 months.
The overall survival (OS) rate was 51 % after 6 months and 29.9 % after 12 months.
Statistically significant factors of better OS after univariable analysis were lower International Union Against Cancer
(UICC) stage at first diagnosis, histology of adenocarcinoma, prior surgery of the primary tumor and lower total BM
volume. After multivariable analysis adenocarcinoma histology remained a significant factor; higher Karnofsky
Performance Score (KPS) and the presence of extracranial metastases (ECM) were also significant.
The RADES II and the NSCLC-RADES indices were significant predictors of OS. However, the NSCLC-RADES failed to
differentiate between intermediate- and low-risk patients. The DS-GPA and GGS were not statistically significant
predictors of survival in univariable analysis.
Conclusion: The ideal prognostic index has not been defined yet. We believe that more specific indices will be
developed in the future. Our results indicate that the histologic subtype of NSCLC could add to the prognostic
value of specialized future indices. The RADES II index had the highest predictive value in the examined patient
cohort.
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Background
Brain metastases (BM) are four to five times more com-
mon than primary intracranial malignancies [1] and 20–
40 % of cancer patients will develop such lesions in the
course of their disease [2]. Non-small cell lung cancer
(NSCLC) is one of the leading causes of BM accounting
for 18–64 % of all lesions [3].
Several factors have led to an increase in the incidence
of BM including an aging population, improvements in
imaging techniques as well as systemic therapies that do
not effectively penetrate the blood–brain barrier [4].
Morbidities caused by BM include neurologic deficits
and cognitive decline and around 20 % of cancer deaths
are linked to intracranial metastases.
Overall prognosis for patients suffering from BM is
generally poor with a median overall survival (OS) of
less than 1 year. However, OS may vary significantly be-
tween different patients depending on prognostic factors
such as performance status, extracranial disease status,
number of metastatic lesions, tumor size, and histology
among others [4]. Several studies have thus tried to
identify prognostic markers in order to identify sub-
groups of patients that are more likely to benefit from
aggressive therapy [5, 6].
Traditionally BM were managed by whole brain radio-
therapy (WBRT), which has been shown to improve sur-
vival as well as quality of life (QOL) [7]. Points of
criticism of WBRT are treatment times of 2–3 weeks,
preclusion of concurrent chemotherapy as well as a de-
cline in neurocognitive function in long-term survivors
[8]. As a consequence, several studies have evaluated the
role of local approaches such as surgery or stereotactic
radiosurgery (SRS), either alone or in combination with
WBRT [9]. Some studies have shown that stand-alone
local therapies minimize neurocognitive long-term im-
pairment and improve QOL without compromising OS
[10]. Other studies have shown higher rates of intracra-
nial relapse but not worse survival rates in patients who
received SRS compared to patients who received a com-
bination of SRS and WBRT [11]. In everyday clinical
practice, WBRT is commonly used for palliative patients,
while local therapies are reserved for patients with lon-
ger life expectancy.
Several authors have tried to develop prognostic indi-
ces in order to facilitate decision making when treating
BM patients. Four recently published indices are the
Golden Grading System (GGS), the disease-specific
graded prognostic index (DS-GPA), the second prognos-
tic index published by Rades et al. in 2011 (RADES II)
as well as the NSCLC-specific index published by
RADES et al. in 2013 (NSCLC-RADES) [12–15]. These
indices are helpful when discussing treatment decisions
of NSCLC BM patients. While the GGS uses the factors
age, Karnofsky Performance Score (KPS) and presence
of extracranial metastases (ECM), the NSCLC DS-GPA
includes these three factors as well as the number of cra-
nial metastases. The RADES II also uses age, KPS, ECM
and number of BM and adds the interval from primary
tumor diagnosis to radiotherapy as a parameter. The
NSCLC-RADES is calculated using the factors gender,
KPS and ECM. These indices have become accepted in
everyday clinical life because most other indices devel-
oped to this date use components that are difficult to
quantify or are subjective (e.g. control of extracranial
disease or BM volume) [6].
It was the aim of this study to evaluate the prognostic
value of these four indices for the NSCLC BM patient
population seen in our department that received stereo-
tactic radiotherapy as primary BM treatment.
Methods
Treatment decisions, patient selection and dose regimens
We performed a retrospective analysis on 90 patients
who underwent stereotactic radiosurgery (SRS) or frac-
tionated stereotactic radiotherapy (FSRT) of intracranial
NSCLC metastases between 04/2004 and 05/2014 and
who had not undergone prior surgery or WBRT for BM.
Follow-up data was analyzed until May 2015.
In our institution, treatment decisions are based on an
interdisciplinary vote and treatment planning is decided
upon individually for every single case. Planning depends
not only on the size of the tumor but also on the loca-
tion and KPS. High single doses were considered SRS
and doses applied in multiple fractions were considered
FSRT. Generally speaking, small tumors with a volume
≤10 ccm or tumors distant to critical structures were
treated with SRS, while larger tumors >10 ccm or tu-
mors in close proximity to critical structures were
assigned to FSRT. However, there could be exceptions
made for individual cases.
Stratification and variables
Patients were stratified according to age, gender, KPS,
histology, International Union Against Cancer (UICC)
stage, number of treated lesions, prior surgery on the
primary tumor, total planning target volume (PTV),
highest biologically effective dose (BED10) per patient,
synchronous vs. metachronous diagnosis of BM
(>1 month after NSCLC diagnosis was considered meta-
chronous), tumor localization, presence of ECM and
interval from BM diagnosis to radiotherapy. The four
prognostic scores DS-GPA, RADES II, NSCLC-RADES
and GGS were calculated.
Salvage therapy after the first radiotherapy was noted
as well. Patients with tumor progress could undergo sal-
vage SRS, WBRT or a resection of the BM.
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Follow-up examinations, including MRI as well as clin-
ical and neurologic examinations were performed at 6–8
week intervals after radiotherapy.
Technical set-up
Patients were treated using Novalis® (BrainLab®) with
beam shaping capability, built-in multi-leaf collimator
(MLC) and image guidance. The Novalis ExacTrac®
image guided frameless system enabled us to image the
patient in any couch position using a frameless position-
ing array. Magnetic resonance imaging (MRI)/ computed
tomography (CT) fusion planning was performed. The
three-dimensional treatment planning system iplanRT®
was used. Gross tumor volume (GTV) was defined as
the area of contrast enhancement on T1-weighted MRI
images, the PTV included a 1–2 mm isotropic safety
margin. If fusion images were considered to be of good
quality, the PTV margin used was only 1 mm. If fusion
images were not considered adequate, a safety margin of
2 mm was used. The dose was prescribed to the 80 %
isodose at the PTV margin.
Formulas and statistics
The BED was calculated for every metastasis treated ac-
cording to the following formula, where n is the number
of fractions and d the dose per fraction. Following the
Linear quadratic model, a value of ten was used for the
α/β-ratio.




OS started with the first day of irradiation and was
estimated using Kaplan-Meier analysis. Subgroups were
compared using the log-rank test for univariable analysis
and the Cox proportional hazard model for multivariable
analysis. A p-value of less than 0.05 was considered
statistically significant. A p-value of less than 0.1 was
considered a trend and was the criterion for inclusion in
multivariable analysis. All statistical analyses were per-
formed using IBM SPSS Statistics 19 (New York, USA).
Results
Patients
Patient characteristics are summarized in detail in Table 1.
90 patients treated for 137 BM in our department be-
tween 04/2004 and 05/2014 were included in the ana-
lysis. The majority of the patients were male (63.3 %)
and the median age was 63 years. Most Patients (71.1 %)
had a good KPS of 70 % or higher. Most patients were
already diagnosed UICC stage IV at the time of cancer
diagnosis (74.4 %) and almost half of the patients showed
synchronous brain metastases (46.7 %). Adenocarcinoma
was the most common histologic subtype of cancer
(61.1 %).
The majority of patients (56.7 %) also showed ECM.
More than half of the patients (61.1 %) were initially
treated for a single brain metastasis. Median total lesion
volume was 2.32 ccm.
Metastases were treated with SRS (78.8 %) or FSRT
(20.4 %). SRS was usually administered with 25.6 Gray
(Gy) (90.7 %). FSRT was mostly conducted in 11 or 13
fractions (64.3 %) and a single dose of 3.8 Gy, resulting
in a total dose of 41.8 or 49.4 Gy. The median of the
highest BED10 per patient was 91.14 Gy (range 20.98–
97.36 Gy).
Overall survival
Of patients alive at last follow-up, median follow-up
time was 14 months. The OS rate was 51 % after
6 months and 29.9 % after 12 months. After 2 and 5
years, 15.7 and 9.1 % of the patients were still alive,
respectively.
The univariable analysis of potential predictive factors
is shown in Table 2. Statistically significant factors of
better OS were lower UICC stage at first diagnosis,
adenocarcinoma histology, lower total BM volume and
prior surgery on the primary tumor. There was a trend
towards better survival rates for lower KPS, metachro-
nous BM and absence of ECM.
In multivariable analysis higher KPS, adenocarcinoma
histology and presence of ECM were significant predict-
ive factors (Table 3).
Prognostic indices
An overview of the prognostic value of the four examined
indices is given in Fig. 1 and Table 4. In our patient
population the RADES II and the NSCLC-RADES index
were significant predictors of OS in univariable analysis,
while the DS-GPA and the GGS were not statistically
significant. However, the NSCLC-RADES failed to differ-
entiate between intermediate- and low-risk patients:
Intermediate-risk patients according to the NSCLC-
RADES showed far better median OS rates than low-risk
patients (10.8 months vs. 5.2 months). High-risk patients
had the worst OS rates (3 months).
Discussion
The question which BM subpopulation benefits from
brain radiotherapy has been a controversial issue [16].
Prognostic indices may be used to identify subpopula-
tions eligible for more intensive therapies. In this study
we retrospectively examined four of the more recently
published prognostic indices in a patient population
treated with SRS or FSRT in our department. These
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indices are simple to calculate and do not rely on sub-
jective variables.
Several studies have tried to compare established prog-
nostic indices for BM patients. In a recent systematic re-
view by Rodrigues et al. from 2013 no index could be
identified as superior [17].
All examined indices (GGS, DS-GPA, RADES II and
NSCLC-RADES) use the KPS and the presence of ECM.
Both variables were highly significant predictors after
multivariable analysis in our patient collective.
The GGS, DS-GPA and RADES II use the factor age,
which was not a significant predictor either in univariable
or in multivariable analysis. Some authors have questioned
the predictive value of the factor age in NSCLC popula-
tions and even the authors of the NSCLC-RADES study
did not find age to be a significant predictor in a
homogenous NSCLC population either [15].
The RADES II as well as the DS-GPA also use the
number of BM, which was not a predictive factor in our
patient collective either. However, the total volume of
BM was highly predictive in univariable analysis. The
first study of prognostic scores for patients in whom




Sex (m/f) 57/33 63.3 %/36.7 %
Age (y) 63.3 (38.9–83)
KPS
100 6 6.7 %
90 12 13.3 %
80 25 27.8 %
70 21 23.3 %
60 6 6.7 %
50 7 7.8 %
n/a 13 14.4 %
Histology
Adenocarcinoma 55 61.1 %
Squamous cell carcinoma 19 21.1 %
Large cell carcinoma 6 6.7 %
Other 8 8.9 %
n/a 2 2.2 %
UICC stage at time of first diagnosis
I 5 5.6 %
II 7 7.8 %
III 7 7.8 %
IV 67 74.4 %
n/a 4 4.4 %
Synchronous BM 42 46.7 %
ECM 51 56.7 %
Number of treated lesions
1 55 61.1 %
2 24 26.7 %
≥ 3 11 12.2 %
Total BM volume (PTV)
per patient (ccm)
2.32 (0.2–45.2)
Highest BED10 per patient 91.14 (20.98–97.36)
Fractionation
SRS 108 78.8 %
FSRT 28 20.4 %
n/a 1 0.7 %
Localization
Temporal lobe 15 10.8 %
Occipital lobe 29 20.9 %
Parietal lobe 34 24.5 %
Frontal lobe 28 20.1 %
Cerebellum 21 15.1 %
Brainstem 5 3.6 %
Table 1 Characteristics of the 90 BM patients analyzed
(Continued)
Basal ganglia 4 2.9 %
n/a 3 2.2 %
Salvage WBRT 13 14.4 %
Salvage SRS or FSRT 10 11.1 %
Salvage resection 5 5.6 %
n/a not available
Table 2 Univariable analysis of potential preditive factors
Log-Rank test
Variable p
Age (< vs. ≥ median) 0.65
Sex 0.42
KPS (< vs. ≥ median) 0.09 (**)
UICC stage 0.020 (*)
Histology (adeno vs. other) 0.016*
Prior surgery 0.001 (*)
Single vs. multiple lesions 0.41
Number of lesions 0.59
Synchronous BM 0.065 (**)
ECM 0.076 (**)
Total BM volume (PTV) per patient,(< vs. ≥ 5ccm) 0.026 (*)
SRS vs. FSRT 0.84
Highest BED10 per patient (< vs. ≥ median) 0.52
Interval PT diagnosis to RT (< vs. ≥ median) 0.17
* p-value ≤ 0.05; ** p-value ≤ 0.1
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SRS alone was used to treat newly diagnosed BM was
published by Likhacheva et al. in 2013 [18]. In their pa-
tient collective, BM volume was a predictive factor for
OS in multivariable analysis, while the number of BM
was not a significant factor [18]. The authors argue that
the decision whether to use stereotactic radiotherapy or
Table 3 Multivariable analysis of potential preditive factors
Variable HR 95 % CI p
KPS (in %, continuous) 0.042 (*)
50 % 7.16 1.61–31.73
60 % 2.52 0.59 - 10.80
70 % 1.09 0.29–4.12
80 % 1.84 0.53–6.45
90 % 1.81 0.46–7.13
100 % (reference)
Histology (adeno vs. other) 0.34 0.17–0.67 0.002 (*)
ECM 2.003 1.09–3.69 0.026 (*)
The analysis included all factors with p-values ≤ 0.1 in the log-rank test.
* p-value ≤ 0.05





RADES II 0.001 (*)
NSCLC-RADES 0.002 (*)
*p-value ≤ 0.05
Fig. 1 Kaplan-Meier analysis of OS rates grouped according to DS-GPA (a), GGS (b), RADES II (c) and NSCLC-RADES (d). Note that group b shows
a shorter median overall survival rate than group c
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WBRT should not be based on the number of BM a
patient presents, but rather on BM volume.
The interval from diagnosis to radiotherapy is only
used in the RADES II, we did however not find it to be
significant either in univariable or in multivariable
analysis.
The NSCLC-RADES is the only examined index
including the factor gender, which was not predictive in
our study.
The factor we found to be the most significant is not
used in any of the examined indices: Adenocarcinoma
histology of the tumor. It must be noted that none of
the studies that led to the definition of the indices exam-
ined here did analyze histological subtypes of NSCLC.
This result is also in accordance with data published by
Kuremsky et al. who showed significant better OS rates
for adenocarcinoma compared to squamous cell car-
cinoma (SCC) [19]. A possible explanation for this
phenomenon is the fact that SCC is often diagnosed at a
higher stage than adenocarcinoma. A second reason might
be the availability of newer systemic agents for adeno-
carcinoma patients (e.g. Pemetrexed and Erlotinib).
To substantiate this possible explanation Kuremsky et al.
compared patients from the pre-Pemetrexed and -Erlotinib
era (before 2005) with patients treated after 2005, however
the authors did not find significant differences.
When comparing our data with the original works by
Sperduto, Rades and Golden, it must be kept in mind
that the patient population examined here is much more
homogeneous in terms of treatment than in the original
works, since we excluded all patients who had received
WBRT or BM resection in the first place. The collective
analyzed in the NSCLC-RADES study was treated with
WBRT only, while we only included FSRT and SRS
patients.
This may to some extent explain the differences in
statistical significance of the examined factors.
The fact that the RADES II and the NSCLC-
RADES gave better results may in part be explained
by the fact that patients are grouped in three classes
instead of four classes as in the DS-GPA and GGS.
Furthermore, the RADES II and the NSCLC-RADES
place more weight on the KPS and the presence of
ECM than the GGS and the DS-GPA, which ap-
peared to be prognostic factors in our study as well
and thus may have contributed to the improved re-
sults for these two scores.
Finally, the limitations of this study should be men-
tioned. Firstly, the retrospective nature of the analysis is
prone to bias. Secondly, the number of patients may
have been too low to find significance of some potential
prognostic factors (e.g. Interval from tumor diagnosis to
radiotherapy) or even of the indices GGS and DS-GPA
themselves.
Conclusion
Multiple prognostic indices for BM patients have been
developed and are currently in use, but the ideal index
has not been defined yet and further research into al-
ternative approaches is needed. Of the indices exam-
ined here, the RADES-II showed the best results for
a SRS and FSRT-treated patient collective with NSCLC
BM. Our results indicate that the factor adenocarcinoma
histology could add to the prognostic value of specialized
future indices.
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